CAMP4 THERAPEUTICS CORPORATION

AI-generated fair value estimate for this company.

Method: Risk-adjusted explicit 10-year cash-flow DCF for a pre-revenue RNA-based gene-regulation biopharma: risk-adjusted cash flows of -$25M/-$20M/-$10M (yrs1-3), turning positive to a risk-adjusted $35M-68M range by yrs5-10 as lead programs could reach commercialization; 13% discount rate; 1% terminal growth; -$84.0M net cash; 62.75M shares outstanding.

Reasoning: Camp4 Therapeutics is a clinical/preclinical-stage biopharma with no current revenue, so a probability-weighted risk-adjusted cash-flow model is the appropriate method rather than a standard FCF DCF; existing cash is added back directly since it does not depend on pipeline success.